AI Article Synopsis
- Chronic hepatitis B treatment can lead to antiviral resistance, with virologic breakthrough as an early sign of resistance development and host immunity playing a role in this process.
- The study reviewed the medical records of patients treated with lamivudine or adefovir, focusing on the relationship between specific HLA-DQB1 alleles and instances of virologic breakthrough.
- Results indicated that patients without virologic breakthrough were more likely to have the DQB1*0503 allele, suggesting that stronger host immunity may improve treatment outcomes and reduce antiviral resistance.
Article Abstract
Background: Chronic hepatitis B treatment with oral antiviral drugs is a long course. During this course, antiviral resistance is a serious issue, particularly, if genetically low barrier drugs are in use. Host immunity is accepted to have an effect on antiviral resistance development. The earliest clinical sign of drug resistance is virologic breakthrough. In this study, we aimed to investigate the relation between HLA-DQB1 alleles and virologic breakthrough events.
Subjects And Methods: The patient records at single institution hepatology clinic were reviewed. Local institution ethics committee approval was taken. The patients' demographic data, virologic parameters, treatment statues were noted. Patients who had received lamivudine or adefovir were recruited and grouped into two according to virologic breakthrough occurrence. Patients who were not compliant to the given treatment were excluded. Blood samples were taken for DNA extraction. HLA-DQB1 alleles were determined at high level by sequence-specific primers-polymerase chain reaction. The distribution of DQB1 alleles among groups was analyzed.
Results: One hundred ninety-eight patients were eligible for the study. Ninety-six of them had virologic breakthrough where 102 did not have. DQB1 0503 allele was more frequent in patients without breakthrough (28.4% vs. 12.4%, P=0.006). In univariate analysis, HBeAg seropositivity (P<0.001), absence of cirrhosis (P=0.007), younger age (P=0.002) and higher pretreatment logDNA (P<0.001) were related to breakthrough events. However, in multivariate analysis only logDNA (P<0.001) and DQB1*0503 (P=0.02) allele revealed statistically significant relation with breakthrough events.
Conclusion: Host immunity may have an effect on outcome during treatment with oral antiviral drugs. A patient with better immunologic profile may suppress the viral replication better and this may cause less resistance occurrence during treatment with genetically low barrier drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinre.2012.10.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand.
Sci Rep
January 2025
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London, WC1E 7HT, UK.
During the COVID-19 pandemic, heterologous vaccination strategies were employed to alleviate the strain on vaccine supplies. The Thailand Ministry of Health adopted these strategies using vector, inactivated, and mRNA vaccines. However, this approach has introduced challenges for SARS-CoV-2 sero-epidemiology studies.
View Article and Find Full Text PDFDownregulation of FcRn promotes ferroptosis in herpes simplex virus-1-induced lung injury.
Cell Mol Life Sci
January 2025
School of Basic Medical Sciences, Xinxiang Medical University, #601 Jinsui Road, Xinxiang, 453003, Henan, China.
Article Synopsis
- HSV-1 infection can lead to lung injury, and a study found that lower levels of FcRn (a protein) are linked to more severe lung damage caused by the virus.
- The study revealed that HSV-1 increases the methylation of the FcRn gene, which reduces its expression by promoting DNMT3b, a protein that inhibits transcription through a specific region of the FcRn promoter.
- Inhibiting ferroptosis (a type of cell death) with a drug helped reduce lung injury in cases affected by HSV-1, indicating that targeting FcRn might be a promising therapeutic approach.
Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough.
Eur J Med Res
January 2025
Department of Ophthalmology, The First Affiliated Hospital of USTC, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Background: The SARS-CoV-2 Omicron variant, since its initial detection, has rapidly spread across the globe, becoming the dominant strain. It is important to study the immune response of SARS-CoV-2 Omicron variant due to its remarkable ability to escape the majority of existing SARS-CoV-2 neutralizing antibodies. The surge in SARS-CoV-2 Omicron infections among most Chinese residents by the end of 2022 provides a unique opportunity to understand immune system's response to Omicron in populations with limited exposure to prior SARS-CoV-2 variants.
View Article and Find Full Text PDFX-Ray Crystallography of Viruses.
Subcell Biochem
December 2024
ALBA Synchrotron Light Source, Cerdanyola del Vallès, Spain.
Since the 1970s and for about 40 years, X-ray crystallography has been by far the most powerful approach for determining virus structures at close to atomic resolutions. Information provided by these studies has deeply and extensively enriched and shaped our vision of the virus world. In turn, the ever-increasing complexity and size of the virus structures being investigated have constituted a major driving force for methodological and conceptual developments in X-ray macromolecular crystallography (MX).
View Article and Find Full Text PDFThe influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment.
Mol Biol Rep
December 2024
Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Immunotherapy, which uses the body's immune system to fight cancer cells, has gained attention recently as a breakthrough in cancer treatment. Although significant progress has been made, obstacles still exist since cancers are skilled at avoiding immune monitoring. The gut microbiota is being looked at more and more in modern research as a critical component in improving the results of immunotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!